A detailed history of Carlson Capital Management transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Carlson Capital Management holds 18,610 shares of IBRX stock, worth $66,996. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,610
Previous 17,800 4.55%
Holding current value
$66,996
Previous $95,000 23.16%
% of portfolio
0.01%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 11, 2024

BUY
$4.82 - $9.15 $3,904 - $7,411
810 Added 4.55%
18,610 $117,000
Q1 2024

Apr 12, 2024

BUY
$3.23 - $6.17 $646 - $1,234
200 Added 1.14%
17,800 $95,000
Q4 2023

Jan 16, 2024

BUY
$1.25 - $5.21 $22,000 - $91,696
17,600 New
17,600 $88,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.44B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Carlson Capital Management Portfolio

Follow Carlson Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carlson Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Carlson Capital Management with notifications on news.